On behalf of Mirati, I’m excited to inform you that adagrasib (KRAZATI®) tablets has received two additional recommendations from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Mirati is committed to advancing investigational uses of adagrasib across lines of therapy in a range of tumor types for the benefit of patients living with KRAS G12C-mutated cancer.
The NCCN Guidelines® now include adagrasib (KRAZATI) as a systemic therapy option for patients with KRAS G12C-mutated advanced colon and rectal cancers (Category 2A). Please find the updated information on page 46 of the NCCN Guidelines for Colon Cancer V.3.2023 and page 59 of the NCCN Guidelines for Rectal Cancer V.5.2023.
With this update, there are now five NCCN Guidelines recommendations for adagrasib (KRAZATI):
NON-SMALL CELL LUNG CANCER (NSCLC)
NCCN Guidelines recommend adagrasib (KRAZATI) as a subsequent therapy option for patients with KRAS G12C-mutated advanced NSCLC after progression (Category 2A). For more information, please review page 44 of the NCCN Guidelines for Non-Small Cell Lung Cancers.
CENTRAL NERVOUS SYSTEM (CNS) CANCERS
NCCN Guidelines recommend adagrasib (KRAZATI) as a systemic therapy option for patients with KRAS G12C-mutated advanced CNS with brain metastases (Category 2A). For more information, please review page 60 of the NCCN Guidelines for Central Nervous System Cancers.
PANCREATIC ADENOCARCINOMA
NCCN Guidelines recommend adagrasib (KRAZATI) as a subsequent systemic therapy option for patients with KRAS G12C-mutated advanced NSCLC with pancreatic adenocarcinoma (Category 2A recommendation for ECOG PS 0-2 and NCCN Category 2B for ECOG PS 3-4). For more information, please review pages 51 and 52 of the NCCN Guidelines for Pancreatic Adenocarcinoma.
COLON CANCER
NCCN Guidelines recommend adagrasib (KRAZATI) plus cetuximab or panitumumab as subsequent therapy for KRAS G12C-mutated advanced or metastatic colon cancer (Category 2A). For patients unable to tolerate an EGFR inhibitor due to toxicity, single-agent adagrasib can be considered (Category 2A). See page 46 of the NCCN Guidelines for Colon Cancer.
RECTAL CANCER
NCCN Guidelines recommend adagrasib (KRAZATI) plus cetuximab or panitumumab as subsequent therapy for KRAS G12C-mutated advanced or metastatic rectal cancer (Category 2A). For patients unable to tolerate an EGFR inhibitor due to toxicity, single-agent adagrasib can be considered (Category 2A). See page 59 of the NCCN Guidelines for Rectal Cancer.
A Category 2A recommendation is based upon lower-level evidence, and there is uniform National Comprehensive Cancer Network® (NCCN®) consensus that the intervention is appropriate. Category 2B is based upon lower-level evidence, and there is NCCN consensus that the intervention is appropriate.
